Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.78 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.78 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009024 | 1.00 | DDB1 (0.78) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3778810 | 0.91 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5136914 | 0.91 | DDB1 (0.83) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382251 | 0.90 | DDB1 (0.75) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12250739 | 0.90 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382415 | 0.90 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12250754 | 0.90 | DDB1 (0.81) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2382414 | 0.89 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL27691490 | 0.89 | DDB1 (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2384176 | 0.88 | DDB1 (0.79) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | claimed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | JUNO THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | JUNO THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | JUNO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240302349-A1 | METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12031975-B2 | Methods of assessing or monitoring a response to a cell therapy | JUNO THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-110290807-B | Methods of determining CAR-T cell dosing | 朱诺治疗学股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2005065455-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CELGENE CORPORATION (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | SIGNAL PHARMACEUTICALS, LLC | 2005-06-30 | — | — | US | disclosed |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
| WO-2005055929-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND MANAGEMENT OF HEMOGLOBINOPATHY AND ANEMIA | CELGENE CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005046318-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-05-12 | — | — | US | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12031975-B2 | Methods of assessing or monitoring a response to a cell therapy | HAVCR2, ICOS, CD47 | DDB1 1700/4885CRBN 754/4885IKZF3 467/4885 |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
| US-20050100529-A1 | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | CA13, CA12, CA14 | DDB1 993/4885CRBN 1923/4885IKZF3 93/4885 |
| US-20250242020-A1 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1) | ROR1, RORB, RORC | DDB1 938/4885CRBN 338/4885IKZF3 82/4885 |
| US-12268741-B2 | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1) | ROR1, RORB, RORC | DDB1 938/4885CRBN 338/4885IKZF3 82/4885 |
| US-20250186503-A1 | METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION | ICOS, MDM2, XIAP | DDB1 1046/4885CRBN 17/4885IKZF3 54/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | DDB1 3650/4885CRBN 1511/4885IKZF3 2/4885 |
| US-20050143344-A1 | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases | SMN1; SMN2, GBA1, AQP4 | DDB1 3913/4885CRBN 1626/4885IKZF3 788/4885 |
| US-20240302349-A1 | METHODS OF ASSESSING OR MONITORING A RESPONSE TO A CELL THERAPY | HAVCR2, ICOS, CD47 | DDB1 1700/4885CRBN 754/4885IKZF3 467/4885 |
| US-20050143420-A1 | administering immunomodulatory compounds; sickle cell anemia or beta -thalassemia; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione | HBG1, HBG2, CD47 | DDB1 62/4885CRBN 2697/4885IKZF3 100/4885 |
| US-12263190-B2 | Methods and combinations for treatment and T cell modulation | ICOS, MDM2, XIAP | DDB1 1046/4885CRBN 17/4885IKZF3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.